Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness.

Philip D Harvey1, Christopher R Bowie

  • 1Mt. Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA. philipdharvey1@cs.com

Expert Opinion on Pharmacotherapy
|March 11, 2005
PubMed
Summary

Ziprasidone, an atypical antipsychotic, effectively treats schizophrenia and mania with cognitive benefits. It shows low weight gain and manageable cardiac concerns, offering sustained relapse prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain Structures and Cognitive Decline: Moderation Analysis of the PACt-MD Randomized Clinical Trial of Brain Stimulation Plus Cognitive Remediation in Older Adults With Remitted Depression or Mild Cognitive Impairment.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2026
Same author

A qualitative exploration of intimacy, romance, and sexuality in early psychosis: needs, barriers, and associations with recovery.

Journal of mental health (Abingdon, England)·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Therapeutic Improvement in People With Schizophrenia Undergoing tACS/CBTp (Transcranial Alternating Current Stimulation/Cognitive Behavioral Therapy for Psychosis) Associated With Usual Medication Regimen: Protocol for a Pilot, Randomized, Single-Blind Trial.

JMIR research protocols·2025
Same author

E-Cog: An online training platform for cognitive health interventions based on the ADDIE model.

Digital health·2025

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Ziprasidone is the fifth atypical antipsychotic available in the US.
  • It functions as a serotonin-dopamine-receptor antagonist with notable 5-HT(2A) and D2 receptor affinity.
  • Agonist activity at the serotonin 5-HT(1A) receptor suggests potential cognitive and affective benefits in schizophrenia.

Purpose of the Study:

  • To review the efficacy and tolerability of ziprasidone.
  • To highlight its approved indications for schizophrenia and acute mania.
  • To discuss its pharmacological profile and long-term outcomes.

Main Methods:

  • Review of pharmacological data.
  • Analysis of clinical trial outcomes for efficacy and tolerability.

Related Experiment Videos

  • Evaluation of long-term data on relapse prevention and cognitive effects.

    • Main Results:

    • Ziprasidone demonstrates short-term antipsychotic efficacy comparable to other atypical antipsychotics.
    • It is associated with low weight gain and minimal impact on lipid and glucose levels.
    • Long-term data indicate successful relapse prevention and sustained cognitive benefits, with QTc prolongation not being a significant issue.

    Conclusions:

    • Ziprasidone is an effective treatment for schizophrenia and acute mania.
    • Its favorable metabolic profile and cognitive enhancement properties are significant advantages.
    • Further research is needed on optimal dosing strategies and administration requirements.